CSS
CDTX

Cubist Systematic Strategies’s Cidara Therapeutics CDTX Stock Holding History

Cubist Systematic Strategies’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-15
Closed -$267 – 3084
2024
Q1 		$267 Buy
15
+4
+36% +$57 ﹤0.01% 3613
2023
Q4 		$181 Buy
11
+7
+175% +$112 ﹤0.01% 3497
2023
Q3 		$84 Buy
+4
New +$79 ﹤0.01% 3247
2022
Q1 		– Sell
-5,902
Closed -$150K – 3575
2021
Q4 		$150K Buy
+5,902
New +$184K ﹤0.01% 3110
2018
Q2 		– Sell
-725
Closed -$58K – 1807
2018
Q1 		$58K Buy
+725
New +$99K ﹤0.01% 1674

Other funds holding CDTX

MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Checkpoint Capital San Francisco, California $279M AUM 45.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Cubist Systematic Strategies's CDTX Position: Q2 2024 in Review

Cubist Systematic Strategies sold out of Cidara Therapeutics (CDTX) in Q2 2024, closing a stake of 15 shares — an estimated $267 sold.

Cubist Systematic Strategies first reported a position in CDTX in Q1 2018 and held it in 5 quarters. The position peaked at $150K in Q4 2021. 26 funds tracked by Wall St. Rank hold CDTX as of Q2 2024.

  • Cubist Systematic Strategies reported no remaining Cidara Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Cubist Systematic Strategies sold 15 Cidara Therapeutics shares in Q2 2024, an estimated $267.
  • Cubist Systematic Strategies first reported a position in Cidara Therapeutics in Q1 2018 and held it in 5 quarters.
  • Cubist Systematic Strategies's Cidara Therapeutics position peaked at $150K in Q4 2021.
  • 26 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q2 2024.

Based on Cubist Systematic Strategies's 13F filing for Q2 2024, filed 14 Aug 2024.